Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)

Trial Profile

Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Pembrolizumab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 12 Dec 2017 Results (n=10) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 Results presented in a TG Therapeutics media release.
    • 01 Nov 2017 According to a TG Therapeutics Inc media release, data from this study have been selected for presentation at the upcoming 59th American Society of Hematology (ASH) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top